# Critical Path Ventures

> Critical Path Ventures is a VC fund in Paris backing Medical, Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 6
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/critical-path-ventures
- Website: https://www.critical-path.fr

Critical Path Ventures is a VC fund in Paris focused on Medical and Health Care. Critical Path Ventures has been supporting seed-stage startups and funding innovative scientific research projects.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Drones | 1 | 17% |
| Mobile | 1 | 17% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Series A | 2 | 33% |
| Series B | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Prophesee | Prophesee is the inventor of the world’s most advanced neuromorphic vision systems.Prophesee’s patented sensors and AI algorithms, introduce a new computer vision paradigm based on how the human eye and brain work. Like the human vision, it sees events: essential, motion information in the scene, not a succession of images.This Metavision®method allows for unprecedented speed (>10 000fps time resolution equivalent), dynamic range (>120dB), data volume (10x to 1000x less) and power efficiency (<10 mW). Prophesee bio-inspired revolution opens a new path to absolute efficiency and safety in autonomous driving, Mobile, IoT and Industry 4.0.Prophesee was founded within iBionext Start-up Studio (Paris) in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch and Luca Verre. The quartet brings a strong combination of experience in image sensing, neuromorphic computing, VLSI design, entrepreneurship and business development. Prophesee is based in Paris, with local offices in Grenoble, Shanghai, Tokyo and Silicon Valley. The company is driven by a team of more than 100 visionary engineers, holds more than 50 international patents and is backed by leading international equity and corporate investors including 360 Capital Partners, European Investment Bank, iBionext, Inno-Chip, Intel Capital, Renault Group, Robert Bosch Venture Capital, Sinovation, Supernova Invest, Xiaomi. | $23.2M | Venture - Series Unknown | Jun 15, 2026 |  |
| Sonomind | Sonomind provides a new treatment method for psychiatric disorders like depression, anxiety, and addiction. | $23.5M | Series A | May 12, 2026 |  |
| Alkion BioInnovations | Alkion BioInnovations was created in March 2017 in order to develop disruptive cannabinoid & pharmaceutical API production using large scale plant tissue production. The team works also on a new sugar replacement: a novel plant-based high intensive protein sweetener. The company won many R&D grants: I-lab, I-Nov, Plan de Relance & EICPhase I; and other prize: La Fabrique Aviva, Netva, Wilco, IPA4SME... | $5.1M | Seed | Nov 21, 2025 |  |
| RDS | RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $16.4M | Series A | Sep 29, 2025 |  |
| Sonomind | Sonomind provides a new treatment method for psychiatric disorders like depression, anxiety, and addiction. | $2.3M | Seed | Sep 24, 2025 |  |
| BrainEver | BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies. | $38.8M | Series B | Jul 03, 2025 |  |

6 of 6 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Capital Grand Est](https://shizune.co/investors/profile/capital-grand-est) — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/eic-fund) — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together
- [iBionext](https://shizune.co/investors/profile/ibionext-network) — VC Fund, 1 deal together
- [MACSF](https://shizune.co/investors/profile/macsf) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Critical Path Ventures invest in?

Critical Path Ventures invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Critical Path Ventures last invest?

The most recent investment recorded for Critical Path Ventures closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co